

Spirify Pharma Presents Novel Compounds at PAINWeek 2020

Naples, FL, September 4, 2020 –

Spirify Pharma Inc., a pharmaceutical company dedicated to transforming the way pain is treated -- without opioids -- will present a poster at PAINWeek 2020, outlining its innovative approach. Developing analogues of a ketamine metabolite – Hydroxynorketamine (HNK) – Spirify aims to effectively and safely reduce intracellular D-Serine levels. D-serine is a potent co-agonist for the NMDA receptor, which is central in the initiation and persistence of chronic pain.

“Our novel family of HNK analogues present a new approach for pain and CNS conditions,” said Dr. Sigal Kremer-Tal, co-founder and Chief Executive Officer of Spirify. “With these compounds we seek to improve upon the great promise which has already been demonstrated for HNK itself in previous studies”

“We are excited to advance our program and believe that these novel compounds will ultimately enhance the utility for this class of drugs” said Joseph Pergolizzi, MD, an international Pain Key-Opinion-Leader and Board member of Spirify. “Pain is the number one reason for patients to seek medical care and we need more safe and effective options.

Dr. Irving Wainer, Spirify’s Chief Scientific Officer is a pioneer in this space, commented: “this program has great potential for addressing pain, depression, and hyperinflammatory disorders.”

Spirify’s presentation at PAINWeek 2020 details:

- September 11-13, 2020: Abstract/poster #46: Ketamine Metabolites in the Treatment of Neuropathic Pain

To find out more about our research presented at PAINWeek please visit:

<https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0149499>

About Spirify:

Spirify is developing and plans to commercialize products that have the potential to effectively treat various CNS conditions, including pain, without the risks of abuse, misuse and diversion seen with opioid analgesics. For more information, visit www.spirifypharma.com.

INVESTOR CONTACT:

Sigal Kremer-Tal, CEO & Co-founder

email: sigaltal2010@gmail.com

Tel: +972 54 323 7445

MEDIA CONTACT:

Roni Appel, COO & Co-founder

email: appel.roni@gmail.com

Tel: +1 201 750 2347